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Background: Pioglitazone reduced progression of coronary atherosclerosis in type 2 diabetes mellitus (DM), but little has been known about 
detailed vessel responses by pioglitazone in patients with non- and early DM.
Methods: Thirty patients (age 64 ± 8 years old, HbA1c 5.9 ± 1.1 %, early DM 36 %) who underwent percutaneous coronary intervention (PCI) were 
randomly assigned into 2 groups of taking pioglitazone (30mg/day) and control. Volumetric and radio-frequency (RF) signal analysis in intravascular 
ultrasound (IVUS) were done for targeted plaques defined as < 50% diameter stenosis with 10-mm length in non-PCI segments and serum lipid 
levels were measured at baseline and 8-month follow-up.
Results: In pioglitazone group, vessel volume (VV) was significantly decreased but lumen volume (LV) did not change. Plaque volume (PV = VV - LV) 
was significantly decreased. Integrated backscatter (IB) value of the plaques in RF analysis was significantly increased, indicating increase of fibrous 
component or decrease of lipid content in the plaques. Serum HDL cholesterol was significantly increased but LDL cholesterol did not change. In 
control group, there was not significant change in those parameters. Table shows changes (Δ = follow-up - baseline) in the data during 8 months.
Conclusions: In non- and early DM patients, pioglitazone makes regression of coronary plaques with preservation of lumen volume (“reverse 
remodeling”) without LDL reduction and it may alter histological plaque components during 8 months.
Changes in IVUS parameters and serum lipid data
Pioglitazone Control p value
Δ LV (mm3) - 1.2 ± 14.7 - 3.6 ± 11.0 0.62
Δ VV (mm3) - 11.1 ± 15.9* - 1.5 ± 14.6 0.07
Δ PV (mm3) - 10.0 ± 4.6* 2.1 ± 8.5 < 0.01
Δ IB value (dB) 2.16 ± 2.93* - 0.96 ± 2.76 < 0.01
Δ LDL (mg/dl) 4.8 ± 28.2 3.6 ± 41.5 0.82
Δ HDL (mg/dl) 11.8 ± 4.6* 4.3 ± 11.5 0.01
Δ TG (mg/dl) -27.5 ± 39.4* 4.1 ± 103.4 0.11
* ; p < 0.05 comparing follow-up with baseline
